Japan’s health ministry has endorsed the first stem-cell therapy derived from induced pluripotent stem cells (iPSCs) for Parkinson’s disease, a decision that could reshape how the world treats one of ...
In April 2026, XellSmart officially launches its multicenter Phase II registrational clinical trial of the "Clinical-Grade, Allogeneic, Off-the-Shelf, iPSC-Derived, Dopaminergic Neural Progenitor Cell ...
Market · GlobeNewswire Inc. The induced pluripotent stem cell (iPSC) market is experiencing robust growth, with a projected ...
With iPSCs continuing to emerge as an important source of starting materials for cell therapy developers, it is crucial to tackle key remaining challenges relating to cell culture scalability and ...
Cellino, a biotechnology firm working on autonomous biomanufacturing for personalized regenerative medicines, has signed a strategic collaboration with Karis Bio, a South Korean cell therapy company, ...
SHANGHAI, March 13, 2026 /PRNewswire/ -- On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured ...
MINNEAPOLIS, Dec. 20, 2023 /PRNewswire/ -- Bio-Techne Corporation (TECH) today announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ...
LONDON--(BUSINESS WIRE)--Mytos, a biotechnology company automating cell manufacturing, today announced new manufacturing collaborations with three innovative biotech companies - StemSight, Rinri ...
DALLAS--(BUSINESS WIRE)--Colossal Biosciences (“Colossal”), the world’s first de-extinction company, announces today that their Woolly Mammoth team has achieved a global-first iPSC (induced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results